bioRxiv · 10.1101/243998
Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform
Abstract
The majority of drugs currently used to treat rheumatoid arthritis (RA) act on a small number of immunomodulatory targets. We applied an integrative biomedical-informatics-based approach and in vivo testing to identify new drug candidates and potential therapeutic targets that could form the basis for future drug development in RA. A computational model of RA was constructed by integrating patient gene expression data, molecular interactions, and clinical drug-disease associations. Drug candidates were scored based on their predicted efficacy across these data types. Ten high-scoring candidates were subsequently screened in a collagen-induced arthritis model of RA. Treatment with exenatide, olopatadine, and TXR-112 significantly improved multiple preclinical endpoints, including animal mobility which was measured using a novel digital platform. These three drug candidates do not act on common RA therapeutic targets; however, links between known candidate pharmacology and pathological processes involved in RA suggest hypothetical mechanisms contributing to the observed efficacy.
Explore related subjects
Keep this discovery
Daugherty, A. C., Farrington, C., Hakin, I., Mujahid, S., Noblin, E. S., Radin, A. M., Chua, M.-S., Rabe, M., Fernald, G., Ford, D., Sirota, M., Schaevitz, L., Radin, A. A.. 2018-01-07. Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform. https://doi.org/10.1101/243998
Cite the original work for its findings. Save a collection to share your selection of sources.